Answers are grounded in this paper and cite their sources.
IN RECENT years androgenic and estrogenic compounds have been employed in the treatment of breast carcinoma (1–7). Previous work has suggested that these hormones may occasionally cause hypercalcemia in patients with osteolytic metastatic mammary carcinoma (6, 8). Spontaneous hypercalcemia occurs not infrequently in debilitated patients suffering from osteolytic lesions secondary to mammary carcinoma. We have encountered six such instances in the past year and in some of these patients there have been recurrent episodes of hypercalcemia associated with nausea and vomiting.1 Since hypercalcemia is the only serious complication reported to date apparently attributable to sex hormone therapy it appeared to be important to establish, if possible, the relationship of these hormones to the production of hypercalcemia. The case histories are reported of four patients, three of whom developed hypercalcemia coincident with the administration of testosterone propionate and one with the administration of diethylstilbestrol. Three patients had mammary carcinoma and one patient had a reticulum-cell sarcoma. They were in the terminal stage of the disease and received hormonal therapy after all other therapeutic measures had been employed.
No takes yet. Share an insight, caveat, or question.
HERRMANN et al. (1949) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: